Last updated on December 2016

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies


Brief description of study

This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced lymphomas and EBV-associated malignancies.

Clinical Study Identifier: NCT01498484

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Susan Prockop, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »